ECSP045472A - "derivados de n-((3-oxo-2,3-dihidro-1h-isoindol-1-il)acetil)guanidina en calidad de inhibidores de nhe-1 para el tratamiento del infarto y la angina de pecho" - Google Patents

"derivados de n-((3-oxo-2,3-dihidro-1h-isoindol-1-il)acetil)guanidina en calidad de inhibidores de nhe-1 para el tratamiento del infarto y la angina de pecho"

Info

Publication number
ECSP045472A
ECSP045472A ECSP045472A ECSP045472A EC SP045472 A ECSP045472 A EC SP045472A EC SP045472 A ECSP045472 A EC SP045472A EC SP045472 A ECSP045472 A EC SP045472A
Authority
EC
Ecuador
Prior art keywords
treatment
derivatives
infarto
dihidro
nhe
Prior art date
Application number
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045472A publication Critical patent/ECSP045472A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invención se refiere a los nuevos compuestos de isoindolona de la fórmula I:en la cual R1 a R6 tienen los significados indicados en las reivindicaciones. Los compuestos de la invención son adecuados como medicamentos antiarrítmicos con un componente cardioprotector para la profilaxis del infarto y el tratamiento del infarto y para el tratamiento de la angina de pecho. Dichos derivados inhiben también de manera preventiva los procesos patofisiológicos asociados con el desarrollo del daño inducido por isquemia, en particular en el desencadenamiento de arritmias cardíacas inducidas por isquemia y de la insuficiencia cardíaca.
ECSP045472 2002-06-03 2004-12-02 "derivados de n-((3-oxo-2,3-dihidro-1h-isoindol-1-il)acetil)guanidina en calidad de inhibidores de nhe-1 para el tratamiento del infarto y la angina de pecho" ECSP045472A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0206783A FR2840302B1 (fr) 2002-06-03 2002-06-03 Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant

Publications (1)

Publication Number Publication Date
ECSP045472A true ECSP045472A (es) 2005-01-28

Family

ID=29558914

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP045472 ECSP045472A (es) 2002-06-03 2004-12-02 "derivados de n-((3-oxo-2,3-dihidro-1h-isoindol-1-il)acetil)guanidina en calidad de inhibidores de nhe-1 para el tratamiento del infarto y la angina de pecho"

Country Status (41)

Country Link
US (2) US7078428B2 (es)
EP (1) EP1528923B1 (es)
JP (1) JP4634793B2 (es)
KR (1) KR101149771B1 (es)
CN (1) CN1290833C (es)
AR (1) AR039927A1 (es)
AT (1) ATE324889T1 (es)
AU (1) AU2003240677B2 (es)
BR (1) BR0311556A (es)
CA (1) CA2488373C (es)
CY (1) CY1105115T1 (es)
DE (1) DE60305042T2 (es)
DK (1) DK1528923T3 (es)
EC (1) ECSP045472A (es)
EG (1) EG24784A (es)
ES (1) ES2261939T3 (es)
FR (1) FR2840302B1 (es)
HN (1) HN2003000162A (es)
HR (1) HRP20041151B1 (es)
IL (1) IL165520A (es)
JO (1) JO2357B1 (es)
MA (1) MA27308A1 (es)
ME (1) MEP27508A (es)
MX (1) MXPA04011931A (es)
MY (1) MY142502A (es)
NO (1) NO329224B1 (es)
NZ (1) NZ536953A (es)
OA (1) OA12864A (es)
PA (1) PA8574701A1 (es)
PE (1) PE20040531A1 (es)
PL (1) PL372188A1 (es)
PT (1) PT1528923E (es)
RS (1) RS51636B (es)
RU (1) RU2318809C2 (es)
SI (1) SI1528923T1 (es)
TN (1) TNSN04237A1 (es)
TW (1) TWI286545B (es)
UA (1) UA81118C2 (es)
UY (1) UY27835A1 (es)
WO (1) WO2003101450A1 (es)
ZA (1) ZA200409094B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531569B2 (en) 2003-12-02 2009-05-12 Sanofi-Aventis Deutschland Gmbh Process for preparing (3-oxo-2,3-dihydro-1H-isoindol-1-yl) acetylguanidine derivatives
DE10356717A1 (de) * 2003-12-02 2005-07-07 Aventis Pharma Deutschland Gmbh Verfahren zur Herstellung von (3-Oxo-2,3-dihydro-1H-isoindol-1-yl)-acetylguanidin-Derivaten
KR100518184B1 (ko) * 2003-12-27 2005-10-04 한국화학연구원 퓨란카보닐구아니딘 유도체, 그의 제조방법 및 그를포함하는 약학적 조성물
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
US20070161648A1 (en) * 2005-10-14 2007-07-12 Hughes Terry V Substituted dihydro-isoindolones useful in treating kinase disorders
TW200812962A (en) * 2006-07-12 2008-03-16 Astrazeneca Ab New compounds I/418
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-842之用途
SA109300358B1 (ar) 2008-06-06 2012-11-03 استرازينيكا ايه بي مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
EP2588104B1 (en) * 2010-07-01 2014-12-10 Merck Sharp & Dohme Corp. Isoindolone m1 receptor positive allosteric modulators
WO2013056015A1 (en) 2011-10-14 2013-04-18 Incyte Corporation Isoindolinone and pyrrolopyridinone derivatives as akt inhibitors
CN103193794B (zh) * 2013-04-12 2016-04-06 中国药科大学 一种异吲哚酮并异噁唑类稠环化合物及其合成方法
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
CN106316922B (zh) * 2016-08-17 2019-02-01 华东师范大学 一种含c-3全取代氧化吲哚衍生物及其合成方法和应用
WO2018058109A1 (en) 2016-09-26 2018-03-29 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
CN110664803B (zh) * 2019-09-19 2023-08-29 中山大学 异吲哚酮类化合物在制备防治溶骨性疾病药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
DE59403818D1 (de) 1993-02-20 1997-10-02 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, als Inhibitoren des zellulären Na+/H+-Austauschs oder als Diagnostikum sowie sie enthaltendes Medikament
FR2735166B1 (fr) * 1995-06-08 1997-08-29 Aerospatiale Procede de fabrication d'un panneau ou analogue a proprietes structurale et acoustique et panneau ainsi obtenu
DE19737224A1 (de) 1997-08-27 1999-03-18 Hoechst Marion Roussel De Gmbh Pharmazeutisches Kombinationspräparat aus einem Inhibitor des Natrium-Wasserstoff-Austauschers und einem Arzneimittel zur Behandlung von Herz-Kreislauferkrankungen
DE19737463A1 (de) 1997-08-28 1999-03-04 Hoechst Marion Roussel De Gmbh Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden
DE19738604A1 (de) 1997-09-04 1999-03-11 Hoechst Marion Roussel De Gmbh Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verminderung der Giftigkeit cardiotoxischer Stoffe
JP2002504546A (ja) 1998-02-27 2002-02-12 ファイザー・プロダクツ・インク 虚血の治療のためのn−[(置換5員ジもしくはトリアザ二不飽和環)カルボニル]グアニジン誘導体
DE19859727A1 (de) 1998-12-23 2000-06-29 Aventis Pharma Gmbh Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verhinderung von altersbedingten Organ-Dysfunktionen, altersbedingten Erkrankungen zur Lebensverlängerung
US6534651B2 (en) * 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
NZ521348A (en) * 2000-04-28 2004-09-24 Pfizer Prod Inc Sodium-hydrogen exchanger type 1 inhibitor (NHE-1)
DE10046993A1 (de) 2000-09-22 2002-04-11 Aventis Pharma Gmbh Substituierte Zimtsäureguanidide, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltendes Medikament
WO2002081443A1 (en) * 2001-04-09 2002-10-17 Chiron Corporation Novel guanidino compounds

Also Published As

Publication number Publication date
DE60305042D1 (de) 2006-06-08
HRP20041151A2 (en) 2005-06-30
PA8574701A1 (es) 2004-05-07
NO20045660L (no) 2004-12-27
EG24784A (en) 2010-09-01
CA2488373C (en) 2012-07-17
HN2003000162A (es) 2004-05-05
RU2318809C2 (ru) 2008-03-10
DK1528923T3 (da) 2006-09-04
US7078428B2 (en) 2006-07-18
CY1105115T1 (el) 2010-03-03
US7589117B2 (en) 2009-09-15
FR2840302B1 (fr) 2004-07-16
EP1528923B1 (en) 2006-05-03
RU2004138789A (ru) 2005-06-27
TNSN04237A1 (en) 2007-03-12
AR039927A1 (es) 2005-03-09
UY27835A1 (es) 2003-12-31
PE20040531A1 (es) 2004-09-27
RS104804A (sr) 2006-12-15
MEP27508A (en) 2010-06-10
JP2005533034A (ja) 2005-11-04
CA2488373A1 (en) 2003-12-11
EP1528923A1 (en) 2005-05-11
MA27308A1 (fr) 2005-05-02
US20060148880A1 (en) 2006-07-06
UA81118C2 (en) 2007-12-10
IL165520A (en) 2009-12-24
JO2357B1 (en) 2006-12-12
KR20050010855A (ko) 2005-01-28
RS51636B (sr) 2011-08-31
CN1658869A (zh) 2005-08-24
FR2840302A1 (fr) 2003-12-05
ZA200409094B (en) 2005-08-31
ES2261939T3 (es) 2006-11-16
BR0311556A (pt) 2005-04-12
KR101149771B1 (ko) 2012-06-08
HK1076383A1 (en) 2006-01-20
NZ536953A (en) 2007-10-26
PT1528923E (pt) 2006-08-31
NO329224B1 (no) 2010-09-20
DE60305042T2 (de) 2007-05-24
PL372188A1 (en) 2005-07-11
ATE324889T1 (de) 2006-06-15
TW200404780A (en) 2004-04-01
OA12864A (en) 2006-09-15
CN1290833C (zh) 2006-12-20
MXPA04011931A (es) 2005-03-31
SI1528923T1 (sl) 2006-08-31
AU2003240677A1 (en) 2003-12-19
HRP20041151B1 (hr) 2013-06-30
AU2003240677B2 (en) 2008-07-17
US20040048916A1 (en) 2004-03-11
MY142502A (en) 2010-11-30
WO2003101450A1 (en) 2003-12-11
IL165520A0 (en) 2006-01-15
TWI286545B (en) 2007-09-11
JP4634793B2 (ja) 2011-02-16

Similar Documents

Publication Publication Date Title
UY27835A1 (es) Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen.
PE20050347A1 (es) Derivados de pirrolopirimidina
ECSP099319A (es) Analogos de tiofeno para el tratamiento o prevencion de las infecciones por flavivirus
BR0312134A (pt) Benzoilguanidinas derivadas de cicloalquilas fluoradas e seu emprego como medicamento
EA200800737A1 (ru) Поперечно связанные соединения циклических аминов и средства для борьбы с вредителями
CY1120995T1 (el) Ετεροκυκλικη ενωση και χρηση αυτης
GT200500225A (es) Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina quinasa
PE20070135A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
ATE478044T1 (de) Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c
CU23210A3 (es) NUEVOS COMPUESTOS DE OXABISPIDINE uTIL EN EL TRATAMIENTO DE ARRITMIAS CARDIACAS
EP2594555A4 (en) HETEROCYCLIC CONNECTION AND P27-KIP-1 DEVICE
SK6532003A3 (en) Ortho-substituted and meta-substituted bis-aryl compounds, method for the production thereof, their use as a medicament, and pharmaceutical preparations containing these compounds
AR089020A1 (es) Agentes de reversion anticoagulante
MEP28908A (en) Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same
CY1109076T1 (el) Παραγωγα της 4- phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline ως φαρμακα για θεραπεια της στειροτητας
EP1500648A4 (en) NEW PIPERIDINE DERIVATIVE
KR101087966B1 (ko) 치환된 티오펜, 이의 제조방법, 및 이를 포함하는 약제학적 조성물
ES2096265T3 (es) Derivados aromaticos de hidroxiamidinas y su empleo como antagonistas del receptor leucotrieno b4.
ES2142895T3 (es) Guanidinas sustituidas con diacilo, procedimiento para su preparacion, su utilizacion como medicamento o agente de diagnostico, asi como medicamento que las contiene.
AR040564A1 (es) Derivados de 3 guanidinocarbonil- 1- heteroaril- indol, procedimiento de preparacion, su uso como medicamentos, y composiciones farmaceuticas que los comprenden
WO2004007478A3 (en) Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use
ES2127875T3 (es) Bencenosulfonil-ureas y -tioureas sustituidas con amino, procedimiento para su preparacion y su utilizacion como productos farmaceuticos.
CR20230437A (es) Nuevos derivados de tiazolopirimidinona
AR043023A1 (es) Derivados de 2,3-benzodiazepina sustituidos
UY29113A1 (es) Benzoilguanidinas sustituidas con pentfluorosulfanilfenilo, procedimientos para su preparacion, su uso como medicamento o agente de diagnostico, y medicamento que las comprende.